V
Valeria Visconte
Researcher at Cleveland Clinic
Publications - 176
Citations - 3423
Valeria Visconte is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 25, co-authored 125 publications receiving 2841 citations.
Papers
More filters
Journal ArticleDOI
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Hideki Makishima,Valeria Visconte,Hirotoshi Sakaguchi,Anna M. Jankowska,Sarah Abu Kar,Andres Jerez,Bartlomiej P Przychodzen,Manoj Bupathi,Kathryn M Guinta,Manuel G. Afable,Mikkael A. Sekeres,Richard A. Padgett,Ramon V. Tiu,Jaroslaw P. Maciejewski +13 more
TL;DR: Mutations affecting spliceosomal genes that result in defective splicing are a new leukemogenic pathway and may constitute diagnostic biomarkers that could potentially serve as therapeutic targets in myelodysplastic syndromes.
Journal ArticleDOI
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska,Hideki Makishima,Ramon V. Tiu,Hadrian Szpurka,Yun Huang,Fabiola Traina,Valeria Visconte,Yuka Sugimoto,Courtney Prince,Christine L. O'Keefe,Eric D. Hsi,Alan F. List,Mikkael A. Sekeres,Anjana Rao,Michael A. McDevitt,Jaroslaw P. Maciejewski +15 more
TL;DR: The results suggest that molecular defects affecting distinct pathways can lead to similar clinical phenotypes in CMML, and single nucleotide polymorphism array increased the diagnostic yield to 60%.
Journal ArticleDOI
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
Fabiola Traina,Valeria Visconte,Paul Elson,Ali Tabarroki,Anna M. Jankowska,Edy Hasrouni,Yuka Sugimoto,Hadrian Szpurka,Hideki Makishima,Christine L. O'Keefe,Mikkael A. Sekeres,Anjali S. Advani,Matt Kalaycio,Edward A. Copelan,Yogen Saunthararajah,S. T. Olalla Saad,Jaroslaw P. Maciejewski,Ramon V. Tiu +17 more
TL;DR: The role of molecular mutations as predictive biomarkers for response and survival in MDS patients treated with DNMT inhibitors is supported.
Journal ArticleDOI
SF3B1 , a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
Valeria Visconte,Hideki Makishima,Anna M. Jankowska,Hadrian Szpurka,Fabiola Traina,Fabiola Traina,Andres Jerez,Christine L. O'Keefe,H. J. Rogers,Mikkael A. Sekeres,Jaroslaw P. Maciejewski,Ramon V. Tiu +11 more
TL;DR: SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts and it is found to be a major factor in the development of central giant cell granuloma.
Journal ArticleDOI
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Valeria Visconte,Heesun J. Rogers,Jarnail Singh,John Barnard,Manoj Bupathi,Fabiola Traina,James E. McMahon,Hideki Makishima,Hadrian Szpurka,Anna M. Jankowska,Andres Jerez,Mikkael A. Sekeres,Yogen Saunthararajah,Anjali S. Advani,Edward A. Copelan,Haruhiko Koseki,Kyoichi Isono,Richard A. Padgett,Sami Osman,Kazunori Koide,Christine L. O'Keefe,Jaroslaw P. Maciejewski,Ramon V. Tiu +22 more
TL;DR: RNA-sequencing analysis of SF3B1 mutants showed differentially used genes relevant in MDS pathogenesis, such as ASXL1, CBL, EZH, and RUNX families, and RNA-sequenced analysis ofSF3B 1 mutants showedDifferentially used genomes relevant inMDS pathogenicity showed altered iron distribution characterized by coarse iron deposits compared with wild-type RARS patients.